🇺🇸 FDA
Pipeline program

Placebo to match IMP TEV-56286, Emrusolmin

TV56286-NDG-20039

Phase 2 small_molecule active

Quick answer

Placebo to match IMP TEV-56286, Emrusolmin for Multiple System Atrophy is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Multiple System Atrophy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials